Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Orgenesis Inc (EM) ORGS

Healthcare Biotechnology Medical Devices
Orgenesis Inc., a biotech company, focuses on cell and gene therapies in the United States. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare model... see more

Current News (EXPM:ORGS)

Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies

ACCESS Newswire March 6, 2025

Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings

ACCESS Newswire January 28, 2025

Orgenesis Provides Third Quarter 2024 Business Update

GlobeNewswire November 13, 2024

Orgenesis Commences Trading on OTCQX® Best Market

GlobeNewswire October 21, 2024

Orgenesis Announces Reverse Stock Split

GlobeNewswire September 23, 2024

Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia

GlobeNewswire August 29, 2024

Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally

GlobeNewswire August 14, 2024

Orgenesis Provides Second Quarter 2024 Business Update

GlobeNewswire August 8, 2024

Orgenesis Provides Business Update for the First Quarter of 2024

GlobeNewswire May 21, 2024
View More News ››

Opinion & Analysis (EXPM:ORGS)

Convergence Will Drive the Ultimate Disruption of Life Sciences

Streetwise Reports March 28, 2018

A new breed of regenerative therapy companies taking hold

Streetwise Reports December 11, 2017
View More Opinion ››

Bullboard Posts (EXPM:ORGS)

ORGS: Unlocking the Potential of Cell and Gene Therapies at

http://beyondspx.com/2024/07/31/orgs-unlocking-the-potential-of-cell-and-gene-therapies-at-the-point-of-care/
MikeTester - August 2, 2024

Much going for the future of this company

Two Noble laureates working for this company, Located in Isreal, a leading cutting edge country in different kinds of research. ...
macman1519 - January 27, 2015

High spec high risk huge possible rewards

Interesting concept, trials in a year, upside monumental and with a son with type 1 , i pray they succeed. Not putting  great deal...
macman1519 - January 27, 2015
View more Bullboard ››

Diagnostear Technologies Inc

Diagnostear Technologies Inc

DiagnosTear Technologies Inc., an ophthalmic company, engages in developing and commercializing disruptive diagnostic ...
View More »